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Gut function remains largely under-investigated in undernutrition, despite its critical role in essential nutrient digestion, 
absorption and assimilation. In areas of high enteropathogen burden, alterations in gut barrier function and subsequent 
inflammatory effects are observable but remain poorly characterised. Environmental enteropathy (EE) – a condition 
that affects both gut morphology and function and is characterised by blunted villi, inflammation and increased 
permeability – is thought to play a role in impaired linear growth (stunting) and severe acute malnutrition. However, 
the lack of tools to quantitatively characterise gut functional capacity has hampered both our understanding of gut 
pathogenesis in undernutrition and evaluation of gut-targeted therapies to accelerate nutritional recovery. Here we 
survey the technology landscape for potential solutions to improve assessment of gut function, focussing on devices 
that could be deployed at point-of-care in low and middle income countries (LMICs). We assess the potential for 
technological innovation to assess gut morphology, function, barrier integrity and immune response in undernutrition 
and highlight the approaches that are currently most suitable for deployment and development. This article focuses on 





Undernutrition has been a part of human experience throughout history and still accounts for 45% of deaths in children 
under the age of 5 [1]. Intuitively, it would be expected that the major manifestations of undernutrition would respond 
to provision of nutrients, but this is not reliably true. Over the last decade, consistent evidence supports the surprising 
conclusion that one widespread manifestation of undernutrition, stunting (impaired linear growth in children [2]), is 
largely refractory to nutritional supplementation. Both systematic reviews and randomised controlled trials support this 
conclusion since only about one tenth of the growth deficit can be corrected by nutritional supplements alone [3-6]. 
Children with wasting (low weight for height), a distinct but often overlapping manifestation of undernutrition, also face 
long-term health defects, which persist despite therapeutic re-feeding. One hypothesis for the resistance of stunting 
and wasting to dietary interventions is that gut dysfunction compromises nutrient availability, uptake and utilisation 
required for healthy growth [7, 8]. Subclinical gut dysfunction in the context of a marginal diet and chronic 
enteropathogen carriage, common in many low and middle income countries (LMICs), is termed “Environmental Enteric 
Dysfunction” (EED) in view of geographical and clinical observations that suggest it is related to environmental 
conditions [9, 10]. The pathological basis of this dysfunction is best referred to as “Environmental Enteropathy” (EE) 
[11]. 
Investigation of EE has been limited hitherto by the need for invasive approaches, including small intestinal 
biopsy, and very few non-invasive tests are in widespread use. EE is characterised by multiple changes in the mucosa of 
the small intestine, though adults and children also have some changes in gastric, and possibly colonic mucosa. Figure 
1A illustrates the pathology of EE (as interpreted by the authors), which includes epithelial damage, leading to loss of 
barrier function with impaired secretory and absorptive function, accompanied by inflammation in the lamina propria 
[12, 13]. To what extent these pathological changes in the gut result in functional changes are yet to be fully understood. 
Figure 1B highlights the key domains and central functions thought to be impacted in EE. One important domain is gut 
permeability, which can be measured by assessing the urinary recovery of orally ingested sugar molecules using tests 
first developed in the 1960s and 70s such as the lactulose:mannitol (L:M) test [14, 15]. However, the L:M test has several 
problems: there are multiple testing protocols leading to difficulties with comparisons between studies, it is time-
consuming, and the assays rely on high-cost and specialised laboratory reagents and equipment that are often 
unavailable at (or near) the point of care [15]. 
Beyond permeability, other biomarkers have also been recognised to be associated with EE and undernutrition 
[16, 17]. Using molecular diagnostics, some of the most promising markers of EE pathophysiology are faecal and 
systemic peptide inflammatory biomarkers [18-22] and growth hormones [21, 22]. However, most existing biomarkers 
provide only a proxy indicator of pathophysiology and immune cell function in undernutrition, and the mechanisms that 
link inflammation to stunting and wasting are poorly characterised [23, 24]. An emerging domain in EE is the gut 
microbiota. Previous work has reported that the gut microbiota follows a patterned progression of maturation during 
the first 2 years of life [25]. Disturbance of this microbial succession, leading to microbiota immaturity, is associated 
with stunted growth and poor outcomes in therapeutic interventions for the most severe manifestation of wasting, 
severe acute malnutrition (SAM; weight-for-height Z-score <-3 and/or bilateral pitting oedema) [25]. An altered gut 
microbiota has also been reported in children displaying EE [26]. Alterations to gut microbiota composition and function 
may influence uptake/utilisation of nutrients and immune defences against enteropathogens, thereby contributing to 
poor childhood growth [27]. However, at present it is unclear if alterations in the gut microbiota drive gut dysfunction 
in malnutrition or are a consequence of aberrations in nutrient assimilation in the proximal gut [28]. Lastly, assessment 
of digestive and absorptive functions has been largely neglected in EE, which is startling given the primary role of the 
small intestine in making essential nutrients from the diet available to the host. 
Current techniques for the assessment of EE largely rely on technologies that require high costs, time, 
infrastructure and expertise. These limitations – combined with the resource-limited settings in which undernutrition is 
most prevalent – indicate that there is an urgent need for new and improved tests. Ideally, such tests should: be easy 
to carry out; give reliable information without the need for specialised equipment/training; be significantly less costly 
than current approaches; generate timely results to guide clinical responses; and be highly informative about specific 
pathophysiological domains. In this review we evaluate a range of emerging technologies that may address these 
challenges and that are suitable for application to the investigation of undernutrition in LMICs. The focus is on systems 
that have the potential to be deployed at the point of care (defined here as devices that are sufficiently simple and user-
friendly to allow use in primary care settings, rural health facilities, or even domestic environments), as these may 
permit large-scale, longitudinal research studies. Such technologies have utility beyond undernutrition and could 
provide valuable new insights into clinical gut pathologies such as inflammatory bowel disease. 
 
 
Improving assessment of gut function 
Direct imaging and sampling of the gut 
Endoscopic imaging capsules 
Beyond work undertaken at a limited number of specialised centres able to perform intestinal biopsies in children, 
relatively little is known about the structural changes in the gut mucosa in EE. In addition, due to ethical reasons and 
the limited access to intestinal tissue, there is an added challenge in defining normal gut morphology in a child, 
particularly at key stages of development such as the introduction of complementary feeding. While numerous 
commercially available clinical imaging techniques exist that are suitable for in-hospital assessment of the morphology 
of the gut mucosa in EE (e.g. endoscopy, confocal laser endomicroscopy, etc. – see [29]), such approaches are invasive 
and hence are unlikely to be deployable in LMICs outside of specialised centres. Capsule-based imaging technologies 
are less invasive and provide comparable imaging capabilities to traditional endoscopes and endomicroscopes. The most 
widely used is wireless capsule endoscopy [30], in which an untethered capsule (approx. 10 mm x 30 mm) is swallowed 
by the patient and records video footage as it passes through the gastro-intestinal tract. While this approach provides 
slightly poorer quality images than standard endoscopy, it is considerably less invasive and safe use has been 
demonstrated in children as young as 10 months [31] (though future use in younger children or larger infant cohorts 
would require further miniaturisation). Furthermore, in combination with appropriate image processing, wireless 
capsule endoscopy can identify villous damage (see Figure 2A&B) with high sensitivity and specificity [32], indicating a 
potential applicability to EE and other clinical conditions where villous damage/remodelling is known to occur. 
Higher resolution imaging capsules also exist and the most advanced (in terms of developmental progress) is 
tethered capsule optical coherence tomography (TC-OCT) [33]. OCT [34] is a structural imaging technology that provides 
depth resolved images at high speed and with resolutions of 10-20 µm (which allow direct imaging of individual villi). In 
TC-OCT, the imaging technology is contained within a capsule that is swallowed by the patient (Figure 2C). This capsule 
is attached to a fibre-optic tether, which is used to deliver/collect light and to retract the capsule once it has descended 
to a desired point in the gastro-intestinal tract. During this pull-back procedure, 3D images are acquired at high speed: 
Key message: the need for improved assessment of gut function 
• Undernutrition is underpinned by a multifaceted breakdown in gut function 
known as environmental enteropathy (EE). 
• Current technologies for assessment of gut function are typically expensive, 
invasive and unsuitable for use at point-of-care in LMICs, meaning that the role 
of the gut in undernutrition is poorly understood. 
• New tools that are deployable at scale in point-of-care settings would be hugely 
beneficial in improving understanding of EE and assessing the impact of 
interventions designed to improve clinical outcomes in undernutrition. 
imaging of the entire oesophagus has been demonstrated within approximately 60 s [33]. Furthermore, large-area 
imaging of the villous morphology in the small intestine has recently been demonstrated without sedation (see Figure 
2D) [35], indicating that TC-OCT has potential applications in EE. 
Finally, tethered capsule confocal laser endomicroscopy systems have also been reported (e.g. [36, 37]), which 
provide higher resolutions than TC-OCT (approx. 1 µm) but with slower imaging speeds. These tethered capsule confocal 
endomicroscopes offer the opportunity to image morphological features of gut dysfunction such as crypt hyperplasia 
and lymphocyte infiltration, which is unlikely to be possible using alternative techniques. 
 
Sampling/biopsy capsules 
Beyond imaging morphological changes in the mucosa, minimally invasive sampling of luminal contents or biopsy 
capabilities would address several domains of EE. Direct assessment of mucosal injury would illuminate tissue and 
cellular changes in EE. Similarly, sampling of the luminal metabolome could identify changes in nutrient digestion and 
absorption, while sampling of the small intestinal microbiota would allow identification of microbial species present in 
the lumen and mucosa. However, endoscopic biopsy represents an expensive, invasive procedure that is unlikely to be 
ethically acceptable in longitudinal studies performed in infants. Carrying out this task using a capsule would be both 
less invasive and more likely to be achievable in longitudinal investigations. 
Prior to the advent of endoscopy, the Crosby-Kugler capsule – a tethered capsule containing a syringe-driven 
knife – was the most common device for collection of tissue biopsies in the gastro-intestinal tract [38], and modified 
capsules were even developed for paediatric use (e.g. [39]). However, use of Crosby-Kugler capsules has ceased due to 
the relative ease with which biopsies can be performed using modern endoscopes. Nonetheless, some minimally 
invasive sampling devices do still exist, with two tethered capsule systems having been commercially available over 
recent years: the Entero-Test (HDC diagnostics) and the Cytosponge (Covidien, e.g. [40]). These are both useful tools 
and, interestingly, the Entero-Test has been applied to studies that have clear relevance to undernutrition and EE: an 
investigation of Tropical Sprue [41] and studies of the upper intestinal microbiota in malnourished children [42, 43]. 
Despite this, both suffer from the limitation that the samples can become contaminated during the withdrawal process 
as the sampling mechanism is not location specific. 
Further devices are under development that aim to offer sample capture with location specificity. For example, 
BioMe Oxford Ltd. (http://www.biome-oxford.com/) are developing an untethered capsule that is designed to collect 
samples from specific locations within the intestine while avoiding the above issues of contamination. In addition, the 
IntelliCap (Medimetrics) – a capsule originally designed for controlled drug release – may also provide the requisite 
location-specific sampling capabilities, and this device now has a CE mark for sampling of intestinal fluid [44] (although 
its dimensions – 11 mm diameter, 26 mm length – will preclude safe use in young children). 
Finally, further research into the development of improved sampling capsules is still underway (for example, 
see the recent review of robotic endoscopic capsules by Cuiti et al. [45]) and one interesting example is the magnetically 
actuated untethered biopsy capsule reported by Simi et al. [46] (see Figure 2E). While such capsules are currently in the 
development phase, they illustrate the potential for wireless, untethered sample/biopsy collection. Thus, in the future, 
this area of research may well yield devices that are ideally suited to the sampling requirements in undernutrition. 
 
Sensing and combination (multifunctional) capsules 
A final topic of interest is the development of sensing capsules and ‘combination’ (multifunctional) capsules. While 
research in this area is somewhat limited, capsules with advanced capabilities for sensing, imaging and/or sampling 
would certainly be of use in phenotyping EE by capturing multiple domains of EE either in targeted (sensing) or 
untargeted (sampling) approaches. 
In terms of sensing (i.e. non-imaging) capsules, a small number have been reported, with some now in clinical 
use. Capsule sensing capabilities available clinically include pH, temperature, pressure and motility, as discussed in the 
recent review by Cummins et al. [47]. Gas sensing capsules have also been reported, which have recently been trialled 
in both animals [48] and humans [49], and which may be well suited to investigation of the microbiota in undernutrition 
(both its composition and metabolic activity). 
In addition, Ovesco Endoscopy AG recently brought to market an ingestible, untethered, sensing pill that 
provides diagnosis of gastro-intestinal bleeding. This device – known as the HemoPill (see Figure 2F&G) – consists of a 
6.5 mm (diameter) x 25.5 mm (length) cylindrical capsule with an active sensing region capable of detecting the 
presence of blood [50]. The sensing is based on optical spectroscopy (in particular, the relative transmission of light of 
two different colours through the sensing region) and the device has been validated in adult volunteers [51]. 
While the detection of gastro-intestinal bleeding may not be of direct relevance to undernutrition, this 
demonstrates the potential to develop wireless sensing capsules for a range of targets. As an example of a potential 
application in undernutrition, a capsule similar to the HemoPill but with fluorescence sensing capabilities could allow 
minimally invasive assessment of gut permeability by detecting the leakage of intravenous fluorescent dyes into the 
intestine (in a similar manner to that reported by Kelly et al. using confocal laser endomicroscopy [52]). Indeed, a 
wireless fluorescence imaging capsule was recently reported by Al-Rawhani et al. [53], indicating that the technological 
development required for this purpose is not unrealistic. 
Multifunctional capsules are even more rare than sensing devices. Nonetheless, capsules with multiple sensing 
capabilities exist – for example, the SmartPill (Medtronic) [54] – and such devices could be useful in undernutrition, with 
possible examples including a wireless capsule endoscope with fluorescence sensing capabilities (to provide localisation 
of intestinal leakage) and/or an imaging capsule with controllable sampling/biopsy capabilities (to permit sampling at 
known locations and correlation with quantification of villous morphology). 
Overall, while capsule technologies provide numerous opportunities for characterising EE in situ with protocols 
that are less invasive than standard endoscopy, all are still likely to require quite advanced clinical facilities. Thus, they 
may help to reduce the invasiveness of undernutrition studies that take place within hospitals or major research centres, 
but are not likely to be suitable for point-of-care use (in primary care centres, rural health facilities or domestic 
environments) in the near future. In addition, large scale use in children/infants will require further miniaturisation. 
Nonetheless, capsule technologies are better suited to use in LMICs than traditional endoscopy/endomicroscopy, simply 
because they are less invasive and can also be less expensive. 
 
Next generation measurements of gut permeability  
Increased gut permeability is thought to be one of the hallmarks of EE but assessment is still reliant on urine sugar 
permeability tests developed in the 1960s and 70s [55]. New techniques such as optical spectroscopy afford the 
opportunity for minimally or non-invasive assessment of human tissue/samples. Specimens are illuminated with light 
and the resulting signals are quantified as functions of wavelength (detailed descriptions can be found elsewhere, e.g. 
[56, 57]). While spectroscopy provides numerous clinical opportunities, it has previously been proposed that the most 
promising application of fluorescence (and reflectance) spectroscopy for undernutrition may be in the measurement of 
intestinal permeability [29]. This approach would involve using transcutaneous fluorescence spectroscopy (i.e. 
fluorescence measurements made through the skin) to assess the uptake of orally ingested contrast agents from the 
gut into the blood stream. This technique is comparable in concept to previous studies performed in animals [58-60] 
and is currently being validated in humans [61]. Briefly, it involves patients drinking an oral dose of a fluorescent contrast 
agent (dye) and a wearable sensor or probe being used to detect and quantify the uptake of the contrast agent from 
the gut into the blood stream. As the rate and degree of uptake are affected by changes in permeability, this approach 
will potentially allow rapid, non-invasive assessment of intestinal permeability, without the need to collect urine 
samples. As discussed previously [29], this method requires further validation, but has the potential to improve upon 
current techniques used to quantify permeability in terms of invasiveness, reliability and ease-of-deployment. 
A further form of optical spectroscopy that may be useful in undernutrition is Raman spectroscopy (see [57, 62, 
63]), which has been used in the detection and classification of bacteria (e.g. [64-68]). While Raman signals are often 
weak in comparison to typical fluorescence or reflectance spectra (meaning that the detection systems are usually more 
advanced and expensive), several handheld Raman spectrometers are nonetheless available commercially at the time 
of writing (e.g. CBEx, Snowy Range Instruments, USA, http://www.wysri.com/cbex/), indicating potential utility for 
point-of-care assessment of bacterial translocation and/or the microbiota in undernutrition. However, to fully realise 
this potential in a point-of-care application, improved sample preparation techniques will be required that can provide 
sufficient signal-to-noise ratios without the need for time-consuming, laboratory-based pre-processing (e.g. similar to 
the protocol recently reported by Boardman et al. for detection of bacteria in blood samples [69]). In addition, for 
analysis of the microbiota, innovative sample collection techniques (e.g. see “Sampling/biopsy capsules” section above) 
may also be beneficial. Interestingly, Raman spectroscopy has also been used for analysis of breath samples (see below), 
indicating that a number of potential development routes exist for application to undernutrition. 
 
The ”omics” picture:  microbiome and metabolome 
Microbiomics 
The pathology of EE is driven, in part, by infection and sub-clinical pathogen carriage [70]. Large, multi-country studies 
have reported that enteropathogen carriage is almost ubiquitous amongst children in LMICs [20, 71] and is associated 
with increased intestinal permeability, enteric inflammation and faltered growth [72]. In addition to pathogenic 
microorganisms, emerging evidence suggests an influential role of the commensal microbiota – and the importance of 
its genetic make-up (often termed the microbiome) – in both EE and child undernutrition [27, 73]. Advances in 
sequencing technologies have facilitated assessments of microbial diversity in EE. 
The rapid development of sequencing technologies has allowed for increased use of culture-independent 
clinical diagnostics of infectious diseases [74]. So-called next-generation sequencing (NGS) technologies – including 
Roche 454 and Illumina platforms (MiSeq, HiSeq, etc.) – have been widely employed for high-throughput analysis of 
mixed metagenomes, particularly those within the gastro-intestinal tract. However, the considerable size, time, cost 
and data output associated with these sequencing approaches renders them largely inappropriate as point-of-care 
technologies and has necessitated cold-chain shipping of samples to sequencing sites outside LMICs. 
To overcome these limitations, Oxford Nanopore Technologies have developed the MinION platform (Figure 
3A): a handheld sequencer that can generate gigabases of long-reads (as opposed to short-reads offered by other NGS 
platforms). The MinION can be powered through a laptop USB port and has significantly cheaper start-up costs 
(approximately $1000) than traditional sequencing platforms. ‘Real-time’ data generation also establishes the MinION 
as an attractive clinical diagnostics tool, which could plausibly identify infectious agents within hours (versus days using 
traditional NGS platforms or culture techniques). Recently, the MinION was successfully utilised for surveillance of an 
Ebola outbreak in Guinea (Figure 3B), with results generated within 24 hours of sample collection and sequencing times 
of 15-60 minutes [75]. The platform has also successfully been used in Antarctica [76] and on the International Space 
Station (Figure 3C) [77], demonstrating its ease of use in remote settings. The MinION has also recently been trialled for 
rapid sequencing of the faecal microbiome in preterm infants at increased risk of sepsis and necrotizing enterocolitis, 
producing results comparable with Illumina MiSeq within 5 hours of sample collection [78]. This approach was also able 
to rapidly assess antimicrobial resistance gene carriage within the microbiome, which poses great potential for clinicians 
to provide targeted antibiotic treatments, an issue that is particularly relevant in the context of SAM. 
Despite the promise of the MinION, it is still limited by multiple factors when compared against traditional NGS 
methods (including coverage depth, error rates and sensitivity) [79, 80]. Furthermore, point-of-care deployment is 
dependent on DNA extraction and library preparation prior to sequencing. However, a new compact Oxford Nanopore 
platform (VolTRAX) is under development to automate library preparation directly from sample input. 
Consistent data are now confirming that enteropathogens have a key influence in undernutrition, yet 
information on the role of the microbiota and microbiome remains sparse. Hence, portable sequencing technologies 
such as the MinION (and the SmidgION, a more compact sequencer designed to connect to a mobile phone) offer 
opportunities to improve understanding of the association between the microbiome and undernutrition through cost- 
and time-effective data collection in point-of-care settings. Where there remains a significant challenge is in 
characterising the functions of the resident microbiota and identifying whether functional niches in the microbial 
community become impaired over time and with increased severity of EE. 
 
Paper strip metabolomics 
The rich data provided by metabolic profiling offers numerous potential opportunities in undernutrition. One solution 
to combining this with point-of-care diagnostics is to develop paper chromatography methods of collecting and/or 
analysing samples in the field. Dried blood, urine or faecal spots deposited on paper substrates, combined with reversed-
phase ultra-performance liquid chromatography and mass spectrometry (UPLC-MS), have been widely investigated with 
varying opinions as to whether the metabolite and sensitivity losses encountered are acceptable with respect to 
diagnosis of specific pathologies. The advantage of dried blood spots or urine strips is that samples can be mailed to 
analysis centres or analysed on site if a suitable instrument is present. This enables patients to collect samples at home 
and can minimize stress to infants and children. 
The use of metabolic profiling of dried blood spots in newborns was explored by several groups in the 1990s 
(e.g. [81]). More recently, an untargeted metabolic profiling method based on liquid chromatography high resolution 
MS was applied to newborn dried blood spots and was able to define characteristic profiles associated with ethnicity 
and birth weight [82]. 
Another recent study compared fresh plasma and urine against dried spots/strips using multiple MS 
approaches [83]. This study reported that paper substrates had only a small impact on the overall MS signals and that 
dried urine spots were inherently more stable than dried blood spots (with the majority of compounds in urine 
remaining stable at room temperature for at least one week post collection). Other papers, however, have reported 
reasonable recovery of metabolic information from blood spots but have suggested a loss of compounds from urine 
spots using negative ionization (e.g. [84]). 
Long term storage (over a 15-year period) has also been evaluated by comparing dried blood spots stored at 
room temperature against serum stored at -80°C, demonstrating degradation of most components in the dried blood 
spots [85]. Hernandes et al. [86] reviewed sample handling and storage procedures for dried blood spots and noted the 
importance of standardizing paper substrates, drying times and storage temperatures, with the recommendation that 
the dried blood spot cards are stored at -20°C or lower. 
In summary, paper strip metabolomics can be used to overcome some of the problems of obtaining high quality 
samples at point-of-care and is attractive because it is reagent free and relatively inexpensive. However, a proportion 
of metabolites are lost meaning that the utility of this method is dependent upon the nature of the specific metabolites 
of interest. 
 
Miniaturised chromatography and mass spectrometry 
There is also a drive towards development of miniaturised chromatographic and direct injection MS systems from the 
perspectives of both hand-held, point-of-care diagnostics and green (sustainable) chemistry. Efforts to miniaturise High 
Performance Liquid Chromatography (HPLC) – e.g. to substantially reduce column diameter [87] or to adopt microfluidic 
technology (www.anywhereHPLC.co.uk) – have resulted in some success, although the technology is currently not 
widely available. 
Microchip electrophoresis has been developed in a miniaturised, portable format that lends itself to clinical 
diagnostics (e.g. [88-90]). However, compared to traditional metabolomics assays, the microfluidic electrophoresis has 
generally focussed on a small number of analytes. Ambient ionization MS was developed in 2004 and enables the user 
to operate without sample preparation or chromatographic separation. This has since been applied to newborn 
screening and monitoring of therapeutic drugs [91]. 
Overall, technology advances in direct injection and ambient MS promise to facilitate the development of 
point-of-care mass spectrometers, which are portable, require low sample volumes and are relatively cheap to run. 
These would be of value for metabolic assessments as well as for other domains of gut dysfunction – for example, as 
breath analysers and for proteomics analysis of immune biomarkers (see below). Various prototype platforms exist, 
however, considerable further development (including further miniaturisation and cost reduction) is required before 
these will be widely deployed in clinical settings in LMICs. 
 
Tracing nutrient digestion and absorption non-invasively 
A limited number of recent studies have successfully employed stable isotope techniques (involving assessment of blood 
samples on mass spectrometry platforms) to measure digestion and absorption of amino acids in both children and 
adults in LMICs (e.g. [92, 93]). Despite this, there is still surprisingly little information in malnutrition on the impact of 
gut dysfunction on the ability to process essential dietary nutrients to make them available to the host. Moreover, it 
remains unclear whether undernutrition, EE and enteropathogen infection overlap to increase requirements for 
essential nutrients as is observed in periods of high nutrient requirements [94]. 
Digestion and absorptive capacity can be assessed using both metabolomic and targeted approaches, and 
breath is an attractive sampling pool for such measurements because it can be sampled non-invasively in children. 
Breath tests can be categorised into untargeted analysis for the characterisation of volatile organic compounds (VOCs) 
or targeted analysis on a single or limited number of gaseous species. Within targeted breath analysis an additional 
functional dimension is accessed through the use of a stable isotope tracer. By sampling the isotope excretion in a 
breath metabolic end-product, the targeted test assesses the functional capacity of a metabolic pathway or 
digestive/absorptive capacity. 
Untargeted breath analysis is an established tool in investigating pulmonary inflammatory disease and 
primarily focusses on breath condensates and VOCs that can be trapped on absorbent materials. The main stay 
analytical technology is mass spectrometry, which requires dedicated centralised facilities (reviewed in [95]), however 
recent efforts to miniaturise gas chromatography-mass spectrometry (GCMS) have been reported [96] (see above). 
Thus, much of the focus in the field has been on gas sample collection and fidelity in storage prior to analysis at a central 
facility such as the Breath Biopsy® (for example, see Figure 4A). Advances such as wafer technology for entrapment of 
selective species by field asymmetric ion mobility mass spectrometry (FAIMS, Owlstone Medical) and electronic nose 
technologies (Sensigent) are attractive but the lack of robust information on which breath biomarkers to utilise in EE is 
a current limitation. 
Targeted breath analysis using stable isotopes to probe the function of a metabolic, bacterial or xenobiotic 
pathway is attractive in undernutrition because of its potential sensitivity and specificity and its relevance to numerous 
domains of gut dysfunction [97]. This paradigm was established by the 13C urea breath test, which has been used 
extensively to map Helicobacter pylori infection at population scales (Figure 4B) [98]. The simplicity of the test – 
administration of a small amount of 13C urea and collection of one or two samples of breath CO2 within 30 minutes – is 
highly attractive in a test demonstrating very high sensitivity and specificity [99, 100], allowing prompt clinical decision 
making. 
Stable isotope breath tests have also been applied to numerous studies relevant to EE and undernutrition. To 
assess the availability of dietary nutrients to meet nutritional requirements, the indicator amino acid oxidation 
technique has been deployed, demonstrating similar lysine requirements in Western [101] and Indian children [102]. 
To what extent these requirements are altered by EE, malnutrition or entropathogens in children is largely unknown, 
although evidence from undernourished men suggests an increased requirement for indispensable amino acids [103, 
104]. 13C-trigylceride digestion was shown to be variable in Jamaican children on admission to hospital and through 
recovery from SAM [105]. In the Gambia, assessment of 13C-starch digestion in weaning children showed that those 
children with weight-for-height Z-scores of less than zero benefited most when supplemented with amylase rich flour-
treated feeds, which suggests impaired starch digestion capacity related to both age and weight [106]. Thus, 
opportunities for the use of breath tests in the study of EE are widespread, but their deployment has been limited to 
date by resource and technical challenges. 
The historical reliance on expensive isotope ratio MS measurements for breath 13CO2 [107], coupled with the 
high technical expertise required to operate such instrumentation, has led largely to the use of centralised facilities for 
breath 13C analysis. Nonetheless, the development of nondispersive infrared (IR) spectrometry for the assessment of 
13C enrichment in CO2 [108] yielded the first site-deployable IR isotope systems (e.g. Kibion IRIS; Exalenz Breath ID; UBiT-
IR300; Heli-FAN/FAN-HP; HEADWAY), which have been utilised in H. pylori community screening programmes in LMICs 
[109]. More recent IR laser-based systems have extended analysis capability to permit assessment of larger sample 
numbers (e.g. Thermo Scientific Delta Ray; Mirico; Picarro; Los Gatos Research). In addition, Raman spectroscopy has 
also been investigated as a tool for rapid analysis of breath samples. For example, Hanf et al. described fibre-enhanced 
Raman spectroscopic (FERS) analysis of exhaled human breath for quantitation of 13CO2 and other breath biomarkers 
(Figure 4C&D) [110]. Further development is still required. However, given the attractiveness of breath sampling for 
diagnostic purposes and the pace of technological innovation, it is highly likely that hand-held breath tests for VOCs and 
isotope-labelled target metabolites are on the horizon. 
 
Gut-associated immune function and inflammation 
Elevated systemic and intestinal inflammatory biomarkers are associated with mortality among children with SAM [111, 
112] and linear growth defects among children growing up in LMICs [19, 22]. Immune function in the gut can be inferred 
indirectly from soluble mediator levels in tissue-specific (e.g. stool, saliva, biopsy) or systemic (blood) samples, but these 
cannot be linked to cellular source or stimulus, limiting their utility for understanding pathogenesis [24, 113]. 
Furthermore, direct assessment of cellular immune function has been extremely limited in studies of undernutrition in 
LMICs to date [23, 113]. 
Significant advances in new technologies for immunology research offer potential to resolve tissue composition 
and function of tissues at a single-cell level (e.g. single cell ‘omics’ [114], multi-photon microscopy [115], 3-dimensional 
tissue culture [116]). For example, single cell transcriptional analysis of gut biopsy specimens from children with Crohn’s 
versus healthy children reveals unique epithelial cell profiles associated with inflammation [117].  Increased 
understanding of pleiotropy and redundancy within networks of immune cells and mediators has also led to adaptation 
of traditional immunology assays to simultaneously assess multiple facets of the immune response rather than one 
biomarker at a time (termed ‘multiplexing’). For example, mass and spectral cytometry allow simultaneous detection of 
>100 cellular markers compared to <30 markers via traditional flow cytometry [118, 119]. However, very few of these 
advances have been translated to undernutrition/EE research and the size, cost and complexity of the associated 
detection hardware is a significant barrier to translating cutting-edge cell- and tissue-immunology methods beyond 
high-income laboratory settings. Notwithstanding the potential for these promising methods, below we focus on 
technological advances/adaptations that are closer to point-of-care/near-point-of-care assessment of gut-associated 
immune function and inflammation in LMICs. 
 
 
Current assays evaluated in cohort studies 
Few inflammation assays and no immune function assays currently meet World Health Organization (WHO) criteria for 
suitable point-of-care tests for resource-limited settings [120]. However, a range of  basic laboratory technologies have 
been used to characterise immune mediators in undernutrition, including: ELISA (enzyme-linked immunosorbent assay) 
[19, 20, 111, 121-123]; quantitative polymerase chain reaction (qPCR) and microarray [124, 125]; GCMS [111, 112]; 
transcriptomics [126]; and flow cytometry [24, 127, 128]. These approaches are routine for assaying a range of 
biomarkers in high-income laboratory settings and, in some cases, provide timely results (hours-days) to inform clinical 
management. However, they remain under-used in adequately-powered cohort studies of undernutrition/EE.  
Organoid tissue culture techniques developed over the past decade use primary stem cells to generate self-
assembling 3-dimensional mini-organs in vitro that more accurately recapitulate the organ environments than 
traditional cell culture. Organoids generated from gut tissue (enteroids or mini-guts) are beginning to be used to model 
EE (e.g. Study of EE and Malnutrition in Pakistan [129]). Informed by transcriptomic studies using duodenal biopsy 
specimens from young children living in rural Pakistan, such organoid systems have shown that gene signatures of 
mucosal leukocyte activation (among other pathways) are associated with wasting [126]. Enteroids would offer a way 
to explore gut leukocyte dynamics in vitro, but can take days-weeks to establish, are subject to high inter-individual 
variability and require tissue culture facilities that may not be available at point-of-care in some settings [130]. 
 
Emerging approaches 
Numerous alternative techniques/approaches are emerging that may be better suited to point-of-care assessment of 
immune function and inflammation. Lateral flow immunoassays (LFIA) are based on membrane strips that take up 
liquid samples by capillary action and detect the presence/absence of specific soluble proteins via recognition elements, 
usually antibodies, embedded in spatially-defined zones. LFIA – already widely used for other conditions – have 
equivalent sensitivity and specificity to ELISA but faster turnaround (minutes versus hours-days) and fewer processing 
requirements. An LFIA-based C-reactive protein (CRP) test has been validated as an indicator of acute phase response 
to infections in SAM [123]. LFIA can be adapted for simultaneous detection of multiple biomarkers via separation of 
detection sites, arraying membrane strips or using reporters with distinct signals [131]. Multiplex LFIA are beginning to 
be used to enhance diagnostics (e.g. CRP and alpha-defensin in periprosthetic joint infection [132]) and could be readily 
adapted for EE (e.g. myeloperoxidase, alpha-1-antitrypsin and neopterin are often assessed together as a combined 
marker of EE [19], but currently rely on separate ELISA). Development of undernutrition-relevant LFIA has been limited 
by a lack of immune biomarker discovery studies [24, 113]. 
Reverse transcription-based loop mediated isothermal amplification (RT-LAMP) uses a series of strand 
displacement steps to allow continuous synthesis of DNA at a constant temperature [133]. In combination with 
development of low-cost folded-paper microfluidics devices for sample preparation, electricity-free heaters [134, 135] 
and LFIA [133], these assays can be used to detect RNA/DNA biomarkers without the need for mains electricity, 
thermocyclers or high-cost detectors required for traditional PCR. RT-LAMP has been trialled for infection diagnosis in 
LMICs (e.g. malaria in whole blood [134] and HIV-1 in plasma [135]) and would also be suitable for immune mediators. 
Few RT-LAMP assays are commercially available and those that are have been reported to perform less consistently 
than PCR [136].  
Smartphone-based detectors use the combination of a light source, high-quality camera and customisable 
software within a smartphone to generate a range of low-cost, portable immunoassay detection platforms (reviewed 
in [137, 138]).  Such detectors would be ideal for LMICs, which can be well-served by mobile phone networks despite 
limited laboratory resources in some settings. Smartphone-based detectors have been validated across a range of 
specimen-types in small-scale studies for one-sample-at-a-time cuvette-based ELISA [139], 3D-printed multiplex ELISA 
[140] and LFIA (Figure 5A) [141], with sensitivity of the latter significantly improved by combination with an image 
processing app [142]. Smartphone-based detectors are also suitable for ‘label free’ biomarker detection methods, which 
directly detect the molecule of interest via electrical, mechanical and/or optical transduction (e.g. wavelength shifts 
induced by antibody binding to immobilised proteins [143]; Figure 5B) rather than addition of a detection reagent [144]. 
Addition of simple hardware can also be used for light and fluorescence microscopy (Figure 5C&D) [145, 146]. Though 
currently low-throughput, smartphone-based detectors could circumvent the size, cost and portability limitations of 
existing immunoassay detectors. 
Portable flow cytometers with automated analysis would bring multi-parameter cellular immunology to the 
bedside. Miniaturisation of detectors and fluidics systems has allowed for straight-forward portable cytometers to be 
generated at low cost [147]. A <$5 USD mobile phone accessory has recently been developed in tandem with a 
disposable microfluidic device to count CD4+ T-cells in <30 µl blood in <30 mins without the need for fluorescent 
labelling, with results comparable to laboratory-based flow cytometers [148]. Suitability for low-volume samples is 
desirable for studies involving sample collection from undernourished children. Existing prototypes require adaptation 
for multi-parameter detection, high-throughput analysis and assay standardisation for point-of-care use. In addition to 
detectors, standardisation of flow cytometry workflows for cell and tissue samples, which can vary widely, is necessary 
for consistent immunoassays across multiple sites and for longitudinal studies (e.g. EuroFlow workflows for leukaemia 
immunobiology [149]). 
Finally, Lab-on-a-chip assays are miniaturised (mm-cm) microfluidics circuits that integrate one or more 
laboratory tests. They are specifically developed for point-of-care use, are relatively low-cost, minimise cell handling 
and assay-to-assay variability, and reduce sample volumes required per assay [150, 151]. Some lab-on-a-chip devices 
have been developed in parallel with smartphone-based detectors [138, 152] (Figure 5E). Commercial lab-on-a-chip are 
available for functional analysis of individual cell types (e.g. neutrophil chemotaxis [153]) and could be used to validate 
and advance observations made in undernutrition using traditional cell culture [23]. Based on organoid techniques, 
miniaturised models are being developed for whole tissues/organs (organ-on-a-chip [154]), including the gut [155]. Gut-
on-a-chip models of undernutrition/EE offer the potential for assessment of mucosal immune cell function in a 
standardised point-of-care format [130]. Lab-on-a-chip has been validated in chronic diseases in high-income settings 
[154]. Gut-on-a-chip populated with epithelial cell-lines (e.g. Caco-2) are commercially available but yet to be validated 





Undernutrition is underpinned by multi-faceted alterations in the functional capacity of the gut, a condition often 
referred to as environmental enteropathy (EE). Although many human conditions and disease states have manifest 
impacts on gut function, surprisingly little characterisation of gut function has been performed in undernutrition 
(beyond a small sub-sample of endoscopic investigations and a handful of biomarkers that are proxies for intestinal 
damage). Technological advances are potentially able to provide a more holistic view of different domains of gut 
dysfunction. Crucially, in EE, greater insight into gut dysfunction would help guide interventions aimed at restoring 
function and limiting the burden of undernutrition in LMICs. 
The developing gut in infancy and later childhood is a highly dynamic organ and greater insight will undoubtedly 
come from minimally invasive methods to assess gut function that can facilitate repeated sampling through key 
development stages. Existing and emerging biomarkers from studies in LMICs (where stunting related to malnutrition, 
EE and enteropathogen burden is prevalent) highlight the complexity of the underlying pathophysiology of stunting. 
Therefore, it may be an unreasonable prospect to expect that a single test or biomarker captures this complexity. 
Crucially, however, deploying multiple new tests that can interrogate numerous complementary aspects of gut function 
simultaneously may help to improve understanding of EE and undernutrition. Here, we have outlined technological 
advances that can overcome the challenges in undertaking research to comprehensively interrogate gut function in 
children and adults with EE in LMICs (in both a static and longitudinal manner). By using such technologies to improve 
understanding of EE (and gut function more broadly) and to monitor responses to interventions, future opportunities 
may also arise to better design interventions and even to identify children most at risk of stunting, thereby allowing 
targeted interventions. 
A broad range of technologies for assessment of gut function are discussed above, and all have relative merits 
in the investigation of EE. The most promising approaches are summarised in Table 1, which assesses each technique in 
terms of the technological readiness level (TRL; based on the scale originally devised by NASA [156] with 9 representing 
Key message: technologies for advanced assessment of gut function 
• A wide range of technologies exist that may facilitate point-of-care 
quantification of gut function in undernutrition. 
• These include capsules for imaging and/or sampling of the gut, spectroscopic 
tools for non-invasive assessment of gut permeability, smartphone-based 
sensors for measurement of immune function, handheld sequencing devices, 
and many others. 
a mature, commercially available technology and 1 representing an initial concept), cost, potential mode of deployment, 
information provided, method for interpretation of results, suitability for use in LMICs, and further development 
needed. Further detail is provided below to explain the potential areas of application, the advances that each technique 
may offer, and the development required to facilitate use in LMICs. 
Imaging capsules represent well validated technologies that have been widely used clinically. Both wireless 
capsule endoscopy and TC-OCT have the potential to provide information on villous morphology, and thus direct 
indications of absorptive surface area and damage, in a manner that is less invasive than standard endoscopy. Moreover, 
images can be processed in an automated way removing the requirement for analysis by an expert gastroenterologist. 
A series of capsules for sampling or biopsy have been reported. The most useful for studies of EE will be those 
that provide location-specific sampling. Although several sampling capsules are under development (e.g. [45]), 
considerable validation is still required to demonstrate the reliability of sample collection and the location specificity. 
Once this work has been undertaken, however, opportunities in EE will be wide-ranging (although the requirement for 
sample analysis may necessitate either advanced facilities on-site or cold-chain shipping of samples to centralised 
analysis facilities). It is likely that all capsules will be best suited to deployment in clinics, however, it may be feasible to 
perform TC-OCT in point-of-care settings as the device’s tether mitigates the risk of capsule retention. While further 
miniaturisation of capsules is highly likely to be necessary to facilitate widespread use in infants, it is noteworthy that 
even deployment in adults would provide important opportunities to improve understanding of the damaged gut in EE. 
Furthermore, given the progress made over recent years in incorporating additional functionality into endoscopic 
capsules (e.g. see “Sensing and combination (multifunctional) capsules” section), further miniaturisation can be 
expected to be feasible if appropriate resources are made available. 
The next technology listed in Table 1 is optical spectroscopy, with both fluorescence and Raman spectroscopy 
highlighted. Transcutaneous fluorescence spectroscopy has been previously suggested as a point-of-care tool for non-
invasive assessment of intestinal permeability [29], where it has the potential to improve upon current tests (e.g. L:M 
tests) in terms of reliability, invasiveness, ease-of-deployment, and even cost. A preliminary demonstration of this 
approach has been reported in rats [60] and human validation is currently underway [61]. However, development of a 
handheld/wearable device that is suitable for point-of-care deployment is still required. 
Raman spectroscopy has the potential to provide advanced information across a number of domains of gut 
dysfunction (e.g. assessment of the microbiota, quantification of bacterial translocation, and analysis of breath 
samples). Handheld devices already exist, but improved sample preparation techniques will be required to allow 
effective point-of-care deployment. In addition, further device development will be required for breath analysis, where 
analyte concentrations are typically low. 
Portable sequencing technologies (e.g. MinION/SmidgION, Oxford Nanopore Technologies) present an 
opportunity to quantitatively analyse the gut microbiome at the point of care, potentially allowing EE measurements 
on a larger scale and in a longitudinal manner. Several hurdles remain, however, including achieving appropriate sample 
preparation, relatively high running costs, and the preparation of libraries for biomarker/metabolite quantitation. In 
addition, sequencing first requires sample collection. In the case of urine, blood or stool samples this is feasible in point-
of-care settings, but collecting gut tissue biopsies is more challenging. Combining portable sequencing systems with the 
sampling/biopsy capsules discussed above may present a solution to this problem. While further 
development/validation of the sampling tools is necessary, the combination of these techniques could significantly 
improve understanding of the role of the microbiome and metabolome in undernutrition. 
 
Table 1. Important technologies for point-of-care assessment of undernutrition. The most promising technologies discussed 
in this article are highlighted here. They are compared against one another in terms of their TRL (technological readiness 
level), cost, the information that they provide, their mode of deployment, the way in which results are interpreted, their 
suitability for use in LMICs, and the further development required. TRL is ranked on a scale of 1-9 (9 represents a mature, 
commercially available technology; 1 represents an initial concept). Mode of deployment is classed as either in-hospital (IH) 
or point-of-care (POC), with point-of-care referring to use in primary care settings, rural health facilities or domestic 
environments. Where necessary, the need to freeze and/or ship samples for analysis is also noted. As costs vary according to 
location and as some technologies have not yet reached market status, costs are provided on a relative scale only (i.e. $, $$ 
or $$$). The suitability for LMICs is rated on a coarse scale of 1-5, with 1 indicating low suitability and 5 high suitability. Scores 
were generated via qualitative assessment based on a range of factors (including cost, ease-of-use, need for sample shipping, 
need for expert analysis, invasiveness, etc.). 
Technology TRL 
Cost 
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Breath tests represent another attractive technology in undernutrition because of their non-invasive sampling. 
Stable isotope breath tests are particularly attractive because of their potential to provide sensitive and specific 
assessment of functional parameters directly related to digestion and assimilation of essential nutrients, a domain of 
gut function that has been largely neglected in undernutrition. At present, samples are generally shipped to centralised 
facilities for analysis, despite availability of some point-of-care systems (e.g. based on IR spectroscopy [108]). Further 
development of these point-of-care analysis systems is required as is identification of the most appropriate breath 
biomarker(s) for assessment of gut dysfunction in undernutrition. Nonetheless, breath tests present clear potential for 
biomarker analysis with non-invasive, longitudinal sample collection. 
Knowledge gaps exist in our understanding of almost all aspects of immune function in undernutrition [23, 
127]. Despite this, consistent relationships have been identified between inflammatory biomarkers and undernutrition 
prognoses and between pathogen carriage and EE. Assessing these (and other) markers at scale has the potential to 
improve understanding of the immunological components of undernutrition/EE and their association with 
enteropathogen carriage. Smartphone ELISA/LFIA are the only techniques for assessment of inflammatory biomarkers 
which are currently deployable at point-of-care, but these are well-validated and widely used in population studies of 
undernutrition. Adaptation of smartphones for microscopy, differential cell counting, flow cytometry and even lab-on-
a-chip analysis is also underway, and such approaches hold promise for point-of-care assessment of a broader range of 
immune functions. 
Finally, we highlight miniaturised systems for metabolomic analysis. Portable mass spectrometers are under 
development but are unlikely to be deployable at scale in LMICs in the foreseeable future. Paper strip metabolomics, 
on the other hand, represents an approach that may be suitable for LMICs. Storing samples on paper strips circumvents 
the need for sample freezing and thus provides opportunities to collect metabolic profiles on large scales (albeit with a 
loss in sensitivity relative to fresh/frozen samples). Importantly, this technology already exists, and the only 
developmental work required will be in assessing the stability of biomarkers relevant to undernutrition. 
Overall, the technologies listed in Table 1 all have merit for the study of EE/undernutrition. While varying levels 
of development are required, the highlighted technologies provide information on elements of gut function ranging 
from villous structure and intestinal permeability to the composition of the microbiota and the expression of 
inflammatory biomarkers. As undernutrition results in multi-faceted (and possibly context specific) aberrations, it is 
important that all (or many) of these domains are investigated simultaneously if we are to truly improve our 
understanding of this complex condition. The techniques highlighted here have the potential to do that across the wide-
ranging domains, and technological development in one area may also facilitate new approaches in others. Thus, it is 
important that these techniques continue to be developed and validated for point-of-care testing in parallel such that, 
in the future, multiple tools can be deployed for simultaneous assessment of complementary aspects of gut function. 




Undernutrition is widespread in LMICs and accounts for approximately 45% of deaths in children under the age of 5 [1]. 
Importantly, provision of food does not reliably solve the problem, with both wasting and stunting being associated 
with a breakdown in gut function that limits essential nutrient availability and increases nutrient requirements. A variety 
of barriers to healthy gut function are evident in populations affected by EE and undernutrition, including chronic 
inflammation, alterations to the gut microbiota, and defects in digestion, gut barrier function and immune-mediated 
Key message: a multi-faceted approach for a complex problem 
• A number of point-of-care diagnostic tools are available or under development 
for assessment of gut function in LMICs. 
• These allow assessment of diverse aspects of gut function including villous 
morphology, gut permeability, immune function, digestion, microbiota, etc. 
• Crucially, these devices must be developed and deployed in combination if we 
are to truly improve understanding of the complex nature of gut dysfunction in 
EE and undernutrition. 
• Finally, while this article focusses on EE/undernutrition, the highlighted 
technologies may also be useful in diagnosis and monitoring of a wide range of 
other gut disorders. 
defence against pathogens. As such, addressing undernutrition requires a multi-faceted approach, potentially including 
treatments to support gut health, sanitary/hygiene interventions, and even redesigning therapeutic feeds to be more 
efficiently digested and absorbed than current nutritional therapies. To achieve this, it will be necessary both to improve 
our understanding of undernutrition and to effectively monitor the impact of interventions over the course of hospital- 
and community-based rehabilitation in a longitudinal manner. This will require tests and diagnostics that are 
minimally/non-invasive, that can assess multiple domains of gut function in parallel, and that, in an ideal world, can be 
deployed in point-of-care settings to allow validation in appropriately powered studies within affected communities. 
In this article, we have reviewed a series of technologies that may be useful for this purpose. Each technology 
has been summarised in terms of the underlying principles and the potential for applications in undernutrition (i.e. in 
terms of the information that could be offered). The devices range from optical imaging systems suitable for deployment 
in hospitals to point-of-care sequencing tools for assessment of diverse biomarkers. Importantly, the information 
provided by the reviewed systems covers several domains of gut functional capacity including villous morphology, 
intestinal permeability, bacterial translocation, inflammation, and even the state of the microbiota and metabolome. 
No one approach is likely to provide a ‘silver bullet’ to the challenge of understanding and monitoring gut dysfunction 
in undernutrition, largely due to the lack of existing information on the most informative indicators of gut pathogenesis. 
However, in combination these technologies have the potential to improve our holistic understanding of gut function 
and to allow monitoring on large scales in affected communities. Thus, prioritising further development and deployment 
of the technologies reviewed here may help to accelerate the development of new/improved interventions to prevent 
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Figure 1. Pathology and domains of gut dysfunction. (A) Diagram illustrating the authors’ interpretation of the 
pathology of EE (blue boxes), showing links to broader features of gut dysfunction and undernutrition (black boxes). 
(B) Domains of gut function that appear to be aberrant in EE. Functional tests that report across each domain may 
shed new light on both the domains of dysfunction and the degree of dysfunction in various forms of undernutrition. 
 
Figure 2. Capsule technologies for imaging, sensing and sampling. (A, B) Wireless capsule endoscopy images of the 
small intestine in (A) a healthy volunteer and (B) a patient with coeliac disease. Images reproduced from [32]. (C) 
Photograph of a tethered capsule OCT (TC-OCT) system. Reproduced from [35]. (D) Example TC-OCT data collected 
in the small intestine demonstrating the capability to provide direct imaging of villi over large areas. Reproduced 
from [35]. (E) Photograph of a magnetically actuated wireless sampling capsule (shown on graph paper for scale). 
Reproduced from [46]. (F, G) Model (F) and photograph (G) of the HemoPill sensing capsule for detection of intestinal 
bleeding. 1 – recess in which blood is detected; 2 – light detector; 3 – light sources; 4 – antenna for data transmission. 
Reproduced from [51]. 
 
Figure 3. Portable sequencing using the MinIon (Oxford Nanopore Technologies). (A) Photograph of the MinION 
handheld sequencing tool developed by Oxford Nanopore Technologies (source: 
https://nanoporetech.com/products/minion). Red arrow indicates where liquid samples are deposited for analysis. 
(B) Photograph of multiple MinION systems deployed for sequencing of Ebola. Reproduced from [75]. (C) Example 
MinION data collected from a mixture of bacterial, viral and mammalian tissue (Mus musculus) material onboard 
the International Space Station demonstrating the suitability for remote deployment. Reproduced from [77].  
 
Figure 4. Point-of-care breath tests. (A) A portable breath sample collection tool (ReCIVA® Breath Sampler, 
Owlstone Medical) for use in conjunction with the Breath Biopsy® central analysis facility (source: 
https://www.owlstonemedical.com/products/reciva/). (B) Helicobacter Pylori infection data collected using a non-
invasive 13C urea breath test in Pakistani infants demonstrating the suitability of breath tests for use in large cohorts. 
Reproduced from [98]. (C) Diagram of a compact and alignment-free gas sensing system based on fibre enhanced 
Raman spectroscopy (FERS). Reproduced from [110]. (D) Example FERS data demonstrating the capability to detect 
and identify 13C at low concentrations. Due to the linear relationship between the FERS signal intensity and gas 
pressure (and because different isotopes exhibit spectral peaks at distinct frequencies), FERS spectra can be 
interpreted to extract concentrations of desired gaseous species (e.g. 13C) simply through quantification of the 
intensity of specific peaks in the spectra (assuming an appropriate calibration procedure has been performed). 
Reproduced from [110]. 
 
Figure 5. Smartphone-based detectors suitable for assessment of immune function (and other biomarkers) at point-
of-care. (A) Image of smartphone-based reader for LFIA strip-based rapid tests for alkaline phosphatase (ALP) activity 
in milk. No ALP is indicated by a visible band, ALP+ samples are indicated by the absence of a band (left). Brightness (Br) 
of bands is quantified on smartphone images using MATLAB® (right). Adapted from [141]. (B) Image of a smartphone 
adapted for use as a spectrometer using a photonic crystal biosensor (left). Schematic of the optical components of the 
detector (centre). Example label-free detection of changes in peak wavelength caused by the binding of a range of 
porcine IgG concentrations to an immobilised layer of protein (right). Low IgG concentration was detected by one 
photonic crystal sensor (green, low sensor) and high IgG concentration by a separate sensor (orange, high sensor). 
Adapted from [143]. (C) Image (left) and schematic (centre) of a smartphone-based light microscope, which could be 
used for differential cell counts or label-free CD4+ T cell detection. Comparative examples of immune cells imaged using 
a standard light microscope versus the smartphone device (right). Adapted from [145]. (D) Image (left) and schematic 
(centre) of a smartphone adapted for use as a fluorescence microscope, which has been trialled for detection of M. 
tuberculosis-infected sputum samples (example of labelled beads shown on right). Adapted from [146]. (E) Example of 
how a Lab-on-a-Chip functional assay can be combined with a smartphone-based detector for point-of-care immune 
function assays. A schematic of the combined device (left: in this example, the Lab-on-a-chip is lined with a renal 
adenocarcinoma cell line for assays of kidney function) and read-outs from two functional assays using the smartphone-
based detector (right: quantification of agglutination in response to a nephrotoxin and fluorescent imaging of cellular 
responses to the same toxin). Adapted from [152]. 
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